Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 19/20 | 0.76 |
| ▸ | CDK1 | P06493 | 1/20 | 0.69 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225462 | 0.93 | MAP3K8 (0.77) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL1224995 | 0.91 | MAP3K8 (0.75) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL1225787 | 0.90 | MAP3K8 (0.73) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL1225448 | 0.90 | MAP3K8 (0.72) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15870667 | 0.89 | MAP3K8 (0.83) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL8176063 | 0.87 | MAP3K8 (0.73) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL1225002 | 0.87 | MAP3K8 (1.00) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL5512304 | 0.84 | MAP3K8 (0.69) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL1225433 | 0.84 | MAP3K8 (0.69) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL5998342 | 0.84 | MAP3K8 (0.69) | MAP3K8CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | MAP3K8 272/4885CDK1 113/4885CCNB1 2256/4885 |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAP3K8 272/4885CDK1 113/4885CCNB1 2256/4885 |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | MAP3K8 498/4885CDK1 143/4885CCNB1 508/4885 |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MAP3K8 272/4885CDK1 113/4885CCNB1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.